Double transgenic Hi-MYC/MPAKT mice also demonstrate the ability of MYC to accelerate AKT-driven prostate tumor growth and this confers resistance to rapamycin treatment [90,94]. This evidence concerns the gene AKT1 and prostate neoplasm.